Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NLS Pharmaceutics AG (NLSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: NLSP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.31% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.25M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 79631 | Beta -0.3 | 52 Weeks Range 1.30 - 16.00 | Updated Date 04/1/2025 |
52 Weeks Range 1.30 - 16.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.74 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -227.76% | Return on Equity (TTM) -862.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7408043 | Price to Sales(TTM) - |
Enterprise Value 7408043 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.02 | Shares Outstanding 4056620 | Shares Floating 457622 |
Shares Outstanding 4056620 | Shares Floating 457622 | ||
Percent Insiders 40.85 | Percent Institutions 17.37 |
Analyst Ratings
Rating 3 | Target Price 6 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NLS Pharmaceutics AG
Company Overview
History and Background
NLS Pharmaceutics AG, founded in 2015, is a Swiss biopharmaceutical company focused on developing innovative therapies for attention deficit hyperactivity disorder (ADHD) and other central nervous system (CNS) disorders. They are developing therapies to focus on the unmet needs of patients with congenital disorders.
Core Business Areas
- ADHD Therapeutics Development: Focused on developing and commercializing investigational therapies for the treatment of ADHD.
- CNS Disorder Therapies: Researching and developing novel treatments for various other CNS disorders.
Leadership and Structure
The leadership team is composed of experienced pharmaceutical executives and scientists. The organizational structure includes departments focused on research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Quilienceu00ae: Quilience (mazindol ER) is designed to treat narcolepsy and has received orphan drug designation. They are also evaluating the effects of Quilience in adults with ADHD. There is currently no market share data publicly available for Quilience as it is an investigational drug. Competitors will include stimulants such as Adderall (Shire/Takeda) and Ritalin (Novartis) if approved for ADHD.
- Mazindol CR: Mazindol CR is another product candidate for ADHD, and potentially other indications. Market share data is not publicly available as it is in development. Competitors will include stimulants such as Adderall (Shire/Takeda) and Ritalin (Novartis).
Market Dynamics
Industry Overview
The ADHD treatment market is a significant and growing market driven by increasing diagnosis rates and awareness of the condition. The CNS disorder market is broad and diverse with numerous therapeutic areas.
Positioning
NLS Pharmaceutics is positioned as a developer of innovative therapies for ADHD and other CNS disorders, focusing on unmet needs. Their competitive advantage lies in its proprietary formulations and focus on specific patient populations.
Total Addressable Market (TAM)
The ADHD therapeutics market is projected to be worth billions of dollars. NLS Pharmaceutics is aiming to capture a portion of this TAM with their novel therapeutic candidates. Exact numbers depend on the specific formulation being offered and geographic sales area.
Upturn SWOT Analysis
Strengths
- Proprietary formulations
- Experienced management team
- Focus on unmet medical needs
- Orphan drug designation for Quilience
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- No currently marketed products
- Small market cap
Opportunities
- Successful clinical trial outcomes
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Growing ADHD market
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Generic entry of existing ADHD medications
Competitors and Market Share
Key Competitors
- TAK
- VTRS
- TEVA
- LILLY
Competitive Landscape
NLS Pharmaceutics faces competition from established pharmaceutical companies with existing ADHD treatments. Its competitive advantage lies in its novel formulations and focus on specific patient populations.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the progression of clinical trials and fundraising activities.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates vary widely, based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing Quilience through clinical trials and exploring partnerships.
Summary
NLS Pharmaceutics is a development-stage company with promising investigational therapies for ADHD and other CNS disorders. The company's success is highly dependent on positive clinical trial outcomes and securing partnerships. Its limited financial resources and competition from established companies pose significant challenges. Success of Quilience will be key to the overall growth of the company.
Similar Companies
- TAK
- VTRS
- TEVA
- LILLY
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports (if available)
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NLS Pharmaceutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-01-29 | Co-Founder, CEO & Director Mr. Alexander Zwyer M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://nlspharma.com |
Full time employees - | Website https://nlspharma.com | ||
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.